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Abstract 
BACKGROUND: The myeloma cell is not able to grow and proliferate out of bone marrow (BM) media, and in 
laboratory conditions its survival is low. We considered to use an environment that has the same conditions as 
body physiological conditions. In this study, the effect of the amniotic membrane (AM) on the growth and 
proliferation of myeloma cells were evaluated. 
METHODS: This study was performed on plasma cells derived from BM aspiration (primary cells) in 3 patients with 
multiple myeloma (MM). Plasma cells of these patients were isolated by magnetic-activated cell sorting (MACS) 
technique and cultured in different environments of AM for two consecutive weeks, and then were examined by 
qualitative polymerase chain reaction (PCR) technique for expression of genes related to proliferation [B-cell 
lymphoma 2 (BCL2)], implantation [chemokine receptor type 4 (CXCR4)], and cell cycle stop (P21, P27). 
RESULTS: Isolated plasma cells were cultured in 3 different groups for 2 weeks. The most cell proliferation was 
observed in the medium containing Roswell Park Memorial Institute (RPMI) medium from amniotic cultures and 
plasma cells [an environment without fetal bovine serum (FBS)]. All genes were expressed on day zero (on the day 
of isolation). On the day 4, proliferation genes (BCL2) and implantation genes (CXCR4) had an expression in the 
control group without FBS medium, but P21 and P27 genes had no expression. 
CONCLUSION: The best environment for the growth and maintenance of plasma cells in vitro is the use of RPMI 
from the AM (without FBS) in which plasma cells can be kept alive for 10 days. 
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Introduction1 
Multiple myeloma (MM) is a type of plasma cell 
malignancy that accounts for about 10% of 
blood cancers. Patients with MM suffer from 
osteoporosis and severe bone pain. Other MM 
symptoms include the secretion of osteoclast 
activating factors (OAF) from malignant plasma 
cells, renal impairment due to increased 
calcium levels and Bence-Jones protein (BJP) 
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excretion, anemia due to replacement of 
malignant cells in the bone marrow (BM) and 
consequently hematopoiesis impairment, and 
recurrent infections due to inefficient 
production of immunoglobulins (Igs).1 
MM microenvironment consists of clonal 
plasma cells, extracellular matrix (ECM), 
proteins, and stromal cells of BM.2 
Myeloma cells express chemokine receptor 
type 4 (CXCR4), which binds to stromal cell-
derived factor 1 )SDF-1(, leading to the 
localization of myeloma cells in BM. SDF-1 is 
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expressed in stromal cells of BM, and by 
signaling through CXCR4, it causes the 
migration and implantation of hematopoietic 
cells. SDF-1 increases the Interleukin-6 (IL-6) 
and, as a result, increases the proliferation of 
the myeloma cells.3 
One of the most effective cytokines in the 
growth of myeloma cells is IL-6, which by 
phosphorylation of the Janus Kinase-Signal 
Transducer and Activator of Transcription 
protein (JAK-STAT) and Mitogen Activated 
Protein Kinase (MAPK) pathways, causes the 
growth of myeloma cells and acts as autocrine. 
Other cytokines that affect myeloma cell 
growth include insulin-like growth factor 1 
(IGF-1), tumor necrosis factor (TNF), IL-10, IL-
15, IL-21R, IL-21, and interferon alfa (IFN-α).4,5 
Myeloma cell growth is an angiogenesis-
dependent process controlled by pro-
angiogenic agents. One of these factors is 
vascular endothelial growth factor (VEGF) 
with a high binding affinity to VEGF receptor 
(VEGF-R). 
For starting the process of angiogenesis, the 
VEGF and epidermal growth factor (EGF) are 
essential, and myeloma cells secrete VEGF 
directly.6,7 
As mentioned, the myeloma cell needs 
proper environment and conditions to maintain 
its survival. The close interaction of myeloma 
cells with BM stromal cells, growth factors, and 
various signaling pathways plays a very 
important role in the development of myeloma. 
Given that outside of this environment and in 
vitro, the myeloma cell is unable to grow and 
reproduce and will not survive, and on the 
basis of many previous studies about MM done 
on the cell line, there is no strong data on the 
primary cell; so, we decided to design a suitable 
environment similar to physiological 
environment of the body for growth and 
reproduction of myeloma cell. As a result, the 
effect of amniotic membrane (AM) on growth, 
proliferation, and survival of myeloma cells has 
been investigated. 
AM has been used for many years as 
clinical scaffolds as well as cellular scaffolds 
due to its many biological properties. 
Finally, in order to investigate the 
proliferation, implantation, and apoptosis of 
myeloma cells, the gene expressions associated 
with these processes have been evaluated. 
Materials and Methods 
The AM sample was taken in sterile conditions 
from healthy women during cesarean section 
with patients' satisfaction in Bahman Hospital, 
Tehran, Iran. The AM sample was transferred 
to the laboratory under sterile conditions 
inside a 50ml Falcon tube containing sterile 
phosphate-buffered saline (PBS) buffer and 
antibiotic at 4 °C (with ice). After clearing the 
AM, the curtain was cut into small pieces 
using a razor blade and a pencil, then placed in 
Roswell Park Memorial Institute (RPMI) 1640 
medium flasks and cultured for 10 days at 37 °C 
in an incubator. The RPMI medium was then 
collected and stored at -80 °C. 
BM aspiration samples of patients with MM, 
referring to the hematology department of the 
Army and Imam Khomeini Hospitals, Tehran 
City, based on the patients' satisfaction and 
permission of the Medical Ethics Committee, 
were collected to 6 cc in sterile vacuum tubes 
containing ethylenediaminetetraacetic acid 
(EDTA) as an anticoagulant and transferred to a 
university lab in an ice bag. 
All of these patients were suspected as cases 
of MM. Therefore, to confirm the presence of 
myeloma cells, the results of flow cytometry 
analysis and aspiration smear were revised. 
The mononuclear cells (MNCs) of the BM 
were separated by ficoll based on the 
difference in density with other blood cells. 
BM aspiration specimens were diluted (1:7) 
in sterile PBS. Then, the diluted sample was 
slowly transferred into the ficoll (the same 
volume of the sample), so that it was not 
mixed with the ficoll. In the next step, the 
Falcon tube containing the blood and ficoll was 
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centrifuged for 35 minutes at 445 rpm at 20 °C 
without brake and acceleration. After the four-
layer centrifugation in the Falcon tube 
consisting of 1) plasma, 2) MNCs, 3) ficoll, and 
4) red blood cells (RBCs) and neutrophils, we 
gently separated the MNCs and accurately 
transferred them to a 50ml conical Falcon tube. 
The cells were washed with 40 ml of PBS 
buffer, completely mixed, and then centrifuged 
at 3000 rpm for 10 minutes at 20 °C. Then, we 
discarded the supernatant precisely. 
To remove the platelets, we remixed the 
cells in 50 ml buffer, and after centrifugation at 
about 200 g for 10-15 minutes at 20 °C, 
carefully removed the supernatant (this step 
increases the cell's purity). 
We mixed the cell pellet for later use in a 
proper volume of buffer. 
Plasma cell isolation with Syndecan-1 
(CD138) index using magnetic-activated cell 
sorting (MACS) technique: At this stage, the 
rapid operation and keeping the cells cool 
prevented non-specific labeling of the cells. 
At first, 8 μl of CD138 microbial antibody 
was added to the pellet in dark and mixed, and 
the falcon tube containing the sample was 
completely covered with foil. The specimen 
was placed at 2-4 °C for 15 minutes. Then, the 
cells were washed with sterile PBS buffer  
(1-2 ml) and centrifuged for 10 minutes at  
20 °C with 300 g. Supernatant was discarded 
precisely. At the next step, we passed the cell 
pellet from the LS column. 
Plasma cell culture in different environments 
from AM: 1. The first group, which was the 
control group, contained RPMI, 10% fetal 
bovine serum (FBS), and plasma cells. 
2. The second group contained RPMI 
derived from AM cultures, 10% FBS, and 
plasma cells. 
3. The third group contained RPMI derived 
from AM cultures and plasma cells. 
Cell count using Neubauer chamber slide: 
Under sterile conditions by slow pipetting,  
10 μl of the suspension was removed from the 
medium and the same volume of trypan blue 
0.4% solution in isotonic buffer with PH = 7 
was added. So, the cells were diluted 2 times. 
Then, both sides of the Neubauer slide were 
filled with it, and we waited a few moments to 
settle down the cells and then studied it with a 
light microscope at 20 magnification. 
Preparation of cellular deposition of the 
isolated plasma cells for extraction of 
ribonucleic acid (RNA): Some amount of the 
sample was poured into 1.5ml microtubes and 
centrifuged at 3000 g for 10 minutes at 20 °C. 
RNA extraction: 1 ml of RNX-Plus was added 
to the suspended or sediment cells, the cells were 
transferred to a 1.5ml microtube, and vortexed 
for 1 minute; after the vortex, the mixture was 
placed at room temperature for 5 minutes. 
The homogenized solution was transferred 
to a 1.5ml microtube and 200 ml chloroform 
was added to each ml of RNX-Plus; tubes were 
recapped firmly and mixed vigorously with 
hand or vortexed for 15 seconds, then 
incubated for 5 minutes at 4 °C. It was then 
centrifuged for 20 minutes at 4 °C at 12000 g. 
The three layers formed after centrifugation 
were the upper aqueous or blue phase 
containing RNA, the intermediate layer 
containing deoxyribonucleic acid (DNA), and 
the underlying layer or the organic phase 
containing proteins. 
Then, the RNA-containing aqueous phase 
was transferred to a 1.5ml RNase-free 
microtube by means of RNase-free 
micropipette tips such precisely that there was 
no contact with the intermediate layer. The 
same as the volume of the aqueous or upper 
phase, 100% isopropanol was added to the 
microtubes, then gently mixed and placed 
overnight at -80 °C. 
Samples were taken out of the freezer and 
then centrifuged at 12000 rpm for 20 minutes 
at 4 °C. 
To completely remove chloroform, RNA 
extract was washed with 70% ethanol. In order 
to wash RNA, 1 ml of 70% ethanol per each ml 
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of RNX-Plus was added to each microtube, 
and the contents of the tubes were well mixed. 
Then, microtubes were centrifuged for 20 
minutes at 4 °C with 12000 g, and supernatant 
solution was excluded. 
RNA should not be completely dried 
because its solubility is reduced. For partial 
drying, the microtube tip was opened for a few 
minutes and before complete evaporation of 
ethanol, RNA was dissolved in 20 µl of RNase-
free distilled water. Then, the microtube was 
incubated for 10 minutes at 55 to 60 °C. 
Quantitative evaluation of the extracted 
RNA: Optical absorption of RNA samples was 
read by a biophotometer at wavelengths of  
280 nm/260 nm and 260 nm/230 nm. 
To read the concentration and absorption of 
the sample, we dissolved 1 μl of the sample in 
49 μl of RNase-free water and multiplied the 
obtained concentration in the dilution factor 
(50). So, we would find out 1 μl of the 
dissolved RNA had how many micrograms of 
RNA. To determine the purity of RNA, the 
optical absorption in 280 nm/260 nm should 
be more than 1.8. If the light absorption of  
280 nm/260 nm is less than 1.8, it indicates the 
RNA contamination with the protein, and it 
should be re-purified. 
The optical absorption of RNA samples at a 
wavelength of 280 nm/260 nm was between 
1.80 to 1.95, indicating the high purity of the 
RNA samples. 
RNA was stored at -80 °C. If the RNA is 
precipitated in ethanol, it will not lose its 
integrity for a long time at -20 °C. 
Synthesis of complementary DNA (cDNA): 
Using the cDNA kit (purchased from Yekta 
Tajhiz Azma Co., Tehran, Iran), the cDNA was 
built from RNA according to the 
manufacturer's kit. 
To say briefly, at first, 1 μl of random 
hexamer was added to an RNA-containing 
solution, and the microtube was incubated for 
5 minutes at 70 °C, the buffer mixture was 
prepared according to protocol: 
4 μl = first standard buffer 
1 μl = deoxynucleoside triphosphate (dNTP)  
1 μl = moloney urine leukemia virus (M-MLV) 
We poured the buffer mixture into each 
tube and filled the volume up to 20 μl. If the 
volume does not reach 20 μl, it should be filled 
with distilled or sterilized water to 20 μl. Then 
the microtubes were spinned shortly and 
incubated for one hour at 42 °C. The cDNA 
was maintained at -20 °C. 
Polymerase chain reaction (PCR) 
All the reagents and solutions used in PCR 
were stored at -20 °C in freezer. To carry out 
the PCR, the reagents and solutions were 
removed from the freezer and placed on the 
ice. After defrosting of the reagents, Master 
Mix was prepared according to the number of 
the samples. 
The PCR solution contained 10 μl ampliqon 
Master Mix, 0.5 μl primer, 1 μl cDNA, and  
8.5 μl distilled water (Table 1). 
 
Table 1. Specifications for utilized primers 
Name Sequence Products length 
CDKN1A-F(P21) CCA GCA TGA CAG ATT TCT ACC 150 
CDKN1A-R(P21) AGA CAC ACA AAC TGA GAC TAA GG 150 
H CXCR4(F) 
Both variants 
CGC CAC CAA CAG TCA GAG 176 
H CXCR4(R) 
Both variants 
AAC ACA ACC ACC CAC AAG TC 176 
H-P27-F CA ACC GAC GAT TCT TCT AC 204 
H-P27-R TGT ATA TCT TCC TTG CTT CAT C 204 
H-BCL2-F CAGGATAACGGAGGCTGGGATG 70 
H-BCL2-R AGAAATCAAACAGAGGCCGCA 70 
HPRT1-F CCT GGC GTC GTG ATT AGT G 125 
HPRT1-R TCA GTC CTG TCC ATA ATT AGT CC 125 
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Electrophoresis of PCR samples on an 
agarose gel: To prepare 30 ml of agarose 
solution, we added 0.6 g of agarose powder to 
30 ml of Tris/Borate/EDTA (TBE) buffer at a 
concentration of 1X in a 100 ml Erlenmeyer 
flask, allowing it to be produced. Then, we 
boiled the suspension in the microwave until it 
was cleared and all agarose particles were 
solved in. 
Then we placed the gel tray in a flat area 
and placed the comb on the gel tray. When the 
molten agarose temperature dropped slightly 
and there was no vapor, 2 μl of the green 
viewer dye was added to the agarose solution 
and dissolved. 
We poured the agarose solution in the gel 
tray and carefully removed the gel comb after 
solidifying, and placed it in the electrophoresis 
tank containing TBE buffer at a concentration 
of 1X, so that the surface of the gel was 
completely covered by buffer. 
Then, we added 10 μl of each PCR product 
in wells. A well is assigned as the DNA 
molecular weight index, which determines the 
size of the PCR product. 
The Mini Run Gel Electrophoresis System 
has two potential differences between 50 V and 
100 V. The device was set to 50 V. Due to the 
negative charge of DNA and thus moving 
toward the positive pole in the electric field, 
the gel was placed in the tank in an order that 
the wells were placed on the negative pole. As 
the green viewer dye reached the end of the 
gel, we turned off the device and placed the 
gel on the digital gel documentation device 
and took a photo after adjusting it (Ethic code: 
IR.TMU.REC.1394.65). 
Results 
After separating plasma cells (with CD138 
index) by MACS technique, a flow cytometric 
technique was used to determine the purity of 
the cells. The results are as follows (Figures 1 
and 2): 
Flow cytometric evaluation results of 
plasma cells after isolation 
 
 
Figure 1. Flow cytometric evaluation results after 
the isolation stage (first patient control group) 
 
The results of cell culture in the AM 
environment and the effect of AM on growth 
and maintenance of myeloma cells 
 
 
Figure 2. Flow cytometric evaluation results 
after the isolation stage (first patient test group) 
 
After isolating the plasma cells using the 
MACS technique and verifying it with flow 
cytometry, the myeloma cells were cultured in 
an AM containing medium in 3 different 
groups for 2 weeks. By trypan blue staining, the 
number of cells was counted per well every 
other day and their growth curves were plotted. 
The first group or control group contained 
RPMI, 10% FBS, and plasma cells. The second 
group contained RPMI product of AM culture, 
10% FBS, and plasma cells. And the third 
group contained RPMI product of AM culture 
and plasma cells. 
The results showed that the AM medium 
without FBS (containing RPMI derived from 
AM culture and plasma cells) was more 
effective on the growth, survival, and 
proliferation of myeloma cells, and they 
survived for 10 days. These results were 
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almost the same in all 3 patients )Figure 3(. 
 
 
Figure 3. Plasma cell culture results of  
3 different patients in different amniotic 
membrane (AM) environments 
 
Results of gene expression in plasma cells 
of individuals with MM: In order to examine 
the expression of genes associated with 
proliferation [B-cell lymphoma 2 (BCL2)], 
implantation (CXCR4), and cell cycle control 
(P21 and P27) on day 0 (day of isolation) and 
on day 4 of cell culture, after preparation of 
cDNA from extracted RNA from the cells of 
the sample, PCR was performed using specific 
primers of each of the genes, the sequences of 
which were listed in the previous section. After 
electrophoresis of PCR products and gel 
photocopying with digital gel documentation, 
the results were as follows. The results of the 
expression of genes in the plasma cells of the 3 
patients were similar (Figures 4-9). 
Results of genes expressions in plasma cells 
of patients: On day zero (isolation day), BCL2, 
CXCR4, P21 and P27, as well as Hypoxanthine-
guanine phosphoribosyltransferase (HPRT) 
genes had expression. On the day 4, control 
group cells expressed BCL2, CXCR4, and HPRT 
genes, but P21 and P27 genes had no expression. 
Similarly, the cells in AM medium without 
FBS (containing RPMI produced from AM 
culture and plasma cells) expressed BCL2, 
CXCR4, and HPRT genes and did not express 
P21 and P27 genes. 
Results of gene expression in first-line plasma 
cells
 
Figure 4. Expression of BCL2, CXCR4, P21 and 
P27, and HPRT genes in plasma cells of the 
patients with multiple myeloma (MM) (first 
patient) on the day 0 (the day of cell separation), 
and on the day 4 in control group 
 
 
Figure 5. Expression of BCL2, CXCR4, P21 and 
P27, and HPRT genes in plasma cells of 
individuals with multiple myeloma (MM)  
(first patient) on fourth day of cell culture  
(FBS-free group) 
 
Results of gene expression in the second patient 
 
Figure 6. Expression of BCL2, CXCR4, P21 and 
P27, and HPRT genes in plasma cells of the 
patients with multiple myeloma (MM) (the 
second patient), on the day zero and on the 
fourth day of cell culture 
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Figure 7. Expression of BCL2, CXCR4, P21 and 
P27, and HPRT genes in plasma cells of 
individuals with multiple myeloma (MM) (the 
second patient) on the fourth day of cell culture 
(FBS-free medium) 
 
The results of gene expression in the plasma 
cells of third patient 
 
Figure 8. Expression of BCL2, CXCR4, P21 and 
P27, and HPRT genes in plasma cells of the 
patients with multiple myeloma (MM) (third 
patient) on the day 0 and fourth day of cell 
culture (control group) 
 
 
Figure 9. Expression of BCL2, CXCR4, P21 and 
P27, and HPRT genes in plasma cells of 
patients with multiple myeloma (MM)  
(third patient) on the fourth day of cell culture 
(FBS-free medium) 
Discussion 
MM is a malignancy associated with plasma 
cells. It is believed that this disorder is caused 
by genetic damages such as chromosomal 
translocations. In addition to genetic changes, 
the microenvironment of the BM plays a role 
in the pathophysiology and malignant growth 
of myeloma cells. The result of the interaction 
between the BM and the myeloma cells is the 
expression of factors that indirectly increase 
the growth of myeloma cells by stimulating 
vascularisation or acting directly as growth 
factors for the malignant cell.8 
The interaction of myeloma cells with BM 
stromal cells causes adhesion, drug resistance, 
and activation of signal transmission 
pathways, which lead to progression of cell 
cycle development and protection of cells 
against apoptosis.9 The myeloma causes 
production and activation of osteoclasts, so 
eliminating bone regeneration. Otherwise, 
osteoclasts by means of intercellular direct 
interactions cause the myeloma cells’ growth 
and survival.10 
The most known growth factor of myeloma 
cell, IL-6, is thought to play a very important 
role in pathogenesis and malignant growth of 
myeloma cells. 
Growth factors and cytokines such as IL-6, 
IGF-1, VEGF, TNF-α, transforming growth 
factor beta (TGF-β), SDF-1, fibroblast growth 
factor (FGF), and IL-21 are considered as a part 
of the pathogenesis of MM which promote 
survival, growth, and migration of the 
myeloma cells as well as the vascularization in 
microenvironments of the BM.11 
Considering myeloma cell properties and 
the role of the microenvironments of BM in 
survival of the myeloma cells, due to the 
presence of growth factors and signaling 
pathways, it is suggested that in vitro growth 
and proliferation of myeloma cells need a 
suitable environment similar to body 
physiologic conditions, so that the myeloma 
cells can survive long outside the body in 
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order to conduct more research on primary 
cells and obtain more beneficial results in 
treating this disease. 
AM has been used in cellular scaffolds for 
many years due to its various biological 
properties and also in clinical studies and 
specifications. AM can also be used in cell 
therapy, because it has the characteristics of 
pluripotent stem cells, the ability of 
differentiation and low immunogenicity, and 
production from the placenta, a post-partum 
discarded tissue. Epithelial and mesenchymal 
cells of AM contain a variety of regulatory 
mediators that promote cell growth, 
multiplication, differentiation, and 
epithelialization, and also inhibition of fibrosis, 
immune rejection, inflammation, and bacterial 
invasion.12 
The specific structure and biological 
survival of the AM in addition to the AM 
matrix and its components, including growth 
factors, have made it an ideal scaffold in tissue 
engineering.13,14 AM matrix contains many 
growth factors including EGF, keratinocyte 
growth factor (KGF), hepatocyte growth factor 
(HGF), FGF, platelet-derived growth factor 
(PDGF), VEGF-R3, TGF-β, and EGF. These 
growth factors create a natural treatment 
environment that accelerates treatment and 
also imitates stem cell niches in growth under 
laboratory conditions. AM secretion of VEGF 
and HGF leads to a good balance between 
TGF-1 and TGF-3 and prevents scar formation 
in the wound, and this property is done by 
tissue regeneration instead of promoting scars 
and fibrosis, and in this way, it can help in 
wounds treatment.15 
Possibly, the presence of these growth factors 
in the AM can play an effective role in the 
proliferation of myeloma cells. In this study, the 
growth and proliferation of plasma cells isolated 
from BM aspiration of 3 patients with MM 
(using MACS technique) were studied for two 
consecutive weeks in 3 different groups of AM. 
Because of the presence of complement 
components and other invasive factors that affect 
cell growth, inactive FBS was used. The result of 
this study showed that the growth and 
proliferation of cells in the first week had an 
increasing process and the highest increase in the 
number of cells was observed in day 10 in the 
AM medium without FBS (containing RPMI 
produced from AM culture and plasma cells). In 
the second week, we saw a declining trend in the 
number of cells. In this study, we used the 
qualitative PCR method to show that plasma 
cells isolated from BM aspiration expressed 
reduction-related genes (BCL2) and 
implantation-related genes (CXCR4) on the 
fourth day of cell culture, and genes related to 
cell cycle control (P21 and P27) were not 
expressed; this was an indication of myeloma 
cell proliferation in the AM environment. Plasma 
cell culture was first launched in the 1970s with 
the aim of conducting research on MM disease. 
Plasma cell culture has since been carried out for 
various purposes, such as the assessment of 
plasma cell malignancies, autoimmune diseases, 
and human therapeutic antibody production. 
Conclusion 
In general, the results of this study are very 
valuable findings applicable in designing of a 
suitable environment similar to the physiologic 
of the body, provided for growth, 
proliferation, and survival of the myeloma 
cells, and also for further assessment. 
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